Neutrophil to Lymphocyte Ratio (NLR) as a biomarker in AHSCT (Autologous Hematopoietic Stem Cell Transplantation) for patients with Systemic Sclerosis: a retrospective multicenter study-NLR3

Health Data Hub declaration number: pending

Data controller : : Assistance publique-Hôpitaux de Paris

Coordinating Investigator : Pr Dominique Farge (Paris Saint-Louis)

Principal investigators in France : Pr Dominique Farge (Paris Saint-Louis), Dr Zora Marjanovic (Paris Saint-Antoine)

Principal investigators in Israel: Pr Doron Rimar (Haifa)

Patient population in France: Systemic sclerosis adult patients treated by autologous hematopoietic stem cell (AHSC) before 01/01/2020, either at St-Louis or at St-Antoine Hospital (AP-HP), with ongoing medical follow-up in France, and having signed an informed consent for the collection of their medical data in the MATHEC-SFGM-TC registry and the use of these data for research purposes.

Research objective : This research involves the analysis of health data already collected as part of the routine care of Systemic Sclerosis patients treated with autologous hematopoietic stem cell transplantation. These data have already been collected in the MATHEC-SFGM-TC registry as well as in the Haifa corresponding database, with the written consent of the relevant patients. The aim of this retrospective data analysis is to assess the role of NLR as a biomarker for clinical outcome and its potential value as a predictor of the observed clinical response and survival in autologous hematopoietic stem cell transplantation in Systemic Sclerosis patients.

To answer the research question, data from 44 patients included in the MATHEC-SFGM-TC registry (France), and 8 patients followed in Haifa (Israel) are planned to be analyzed.
Information for patients included in the study in France: In accordance with the informed consent previously signed by each patient, their agreement has been obtained for the use of their data for research purposes.

Right for opposition:
Patients may contact the study coordinating investigator or a team member to apply their right to be opposed to this study:
– By email at the following address: dominique.farge-bancel@aphp.fr; ingrid.munia@aphp.fr
– By telephone at +33 (0)142385093
– By post at the following address: Unité de Médecine Interne (UF 04): CRMR MATHEC, Maladies Auto-immunes et Thérapie Cellulaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France.

Should you encounter any difficulties in exercising your rights, please contact the AP-HP Data Protection Officer at the following address: protection.donnees.dsi@aphp.fr